Search

The World Health Organization (WHO) has recently published a new lung cytopathology reporting system, which simplifies the diagnostic categories into a five-tier system without subcategorization. The system encourages the use of ancillary diagnostic tests for better categorization of specimens and further management. This correspondence provides a brief outline of the lung reporting system, including standardized nomenclature and the use of terminologies harmonizing with the WHO Blue Book. The system includes categories such as non-diagnostic, benign, atypical, suspicious for malignancy, and malignant, with corresponding risk-based management strategies for clinicians. Ancillary techniques like immunocytochemistry can assist in upgrading the category from suspicious for malignancy to malignancy. The system aims to provide universal simplified criteria for categorizing lung cytology samples and their management options. [Extracted from the article]

This article discusses the development of a new reporting system for lymph node cytopathology by the World Health Organization (WHO). The system aims to use standardized nomenclature and terminology that aligns with the WHO Blue Book on hematolymphoid tumors. The article explains the process of collaboration between the International Academy of Cytology (IAC), the International Agency for Research on Cancer (IARC), and the WHO to create this system. It also provides an outline of the possible interpretation categories within the reporting system, including insufficient/inadequate/nondiagnostic, benign, atypical, suspicious for malignancy, and malignant. The authors believe that implementing this standardized reporting system will improve the quality of diagnostic assessment and communication between cytopathologists and clinicians. [Extracted from the article]